Landecho Manuel F, Colina Inmaculada, Huerta Ana, Fortuño Ana, Zalba Guillermo, Beloqui Oscar
Departamento de Medicina Interna, Clínica Universidad de Navarra, Pamplona, Navarra, España.
Rev Esp Cardiol. 2011 May;64(5):373-8. doi: 10.1016/j.recesp.2010.11.011. Epub 2011 Apr 9.
Advanced kidney disease is a major health problem due to its association with high cardiovascular morbidity and mortality. Early recognition of advanced kidney disease is the mainstay to avoid its progression. Since metabolic syndrome and insulin resistance are risk factors for both cardiovascular and advanced kidney disease, we investigated the relationship of early kidney disease (EKD) with metabolic syndrome and insulin resistance, and their association with surrogate markers of arteriosclerosis.
We studied 1498 subjects. Insulin resistance was defined as HOMA ≥3.7 mmol (μU)/L(2) and EKD as stages 1 and 2 of the NKF-KDOQI. Carotid intima-media thickness was used as a surrogate marker of arteriosclerosis.
The presence of one trait of metabolic syndrome was associated with an odds ratio (OR) for EKD of 2.3 (95% confidence interval [CI], 1.18-4.48) that increased to 6.72 (95% CI, 3.56-13.69) in subjects with the syndrome. All the traits of the syndrome except low level of high-density lipoproteins showed an increased OR for EKD. Increasing HOMA was also directly correlated with higher OR for EKD, being as high as 3.89 (95% CI, 1.99-7.59) for subjects in the fourth quartile. Subjects with the syndrome plus EKD showed an increased intima-media thickness compared with those without kidney disease.
Insulin resistance and all metabolic syndrome traits except low level of high-density lipoproteins were significantly associated with an increased OR for EKD. Both metabolic syndrome and EKD were independently and additively related to the presence of surrogate markers of arteriosclerosis.
晚期肾病是一个主要的健康问题,因其与心血管疾病的高发病率和高死亡率相关。早期识别晚期肾病是避免其进展的关键。由于代谢综合征和胰岛素抵抗是心血管疾病和晚期肾病的危险因素,我们研究了早期肾病(EKD)与代谢综合征和胰岛素抵抗的关系,以及它们与动脉硬化替代标志物的关联。
我们研究了1498名受试者。胰岛素抵抗定义为稳态模型评估法(HOMA)≥3.7 mmol(μU)/L²,EKD定义为美国国家肾脏基金会-肾脏病预后质量倡议(NKF-KDOQI)的1期和2期。颈动脉内膜中层厚度用作动脉硬化的替代标志物。
代谢综合征的一个特征的存在与EKD的比值比(OR)为2.3(95%置信区间[CI],1.18 - 4.48)相关,在患有该综合征的受试者中该比值比增加到6.72(95% CI,3.56 - 13.69)。除高密度脂蛋白水平低外,该综合征的所有特征均显示EKD的OR增加。HOMA升高也与EKD的较高OR直接相关,处于第四四分位数的受试者的OR高达3.89(95% CI,1.99 - 7.59)。与无肾病的受试者相比,患有该综合征加EKD的受试者内膜中层厚度增加。
胰岛素抵抗以及除高密度脂蛋白水平低外的所有代谢综合征特征均与EKD的OR增加显著相关。代谢综合征和EKD均与动脉硬化替代标志物的存在独立且相加相关。